NASDAQ:ICCC ImmuCell Q4 2024 Earnings Report $5.50 +0.01 (+0.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.50 0.00 (-0.09%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History ImmuCell EPS ResultsActual EPS$0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuCell Revenue ResultsActual Revenue$7.75 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuCell Announcement DetailsQuarterQ4 2024Date2/25/2025TimeAfter Market ClosesConference Call DateWednesday, February 26, 2025Conference Call Time9:00AM ETUpcoming EarningsImmuCell's Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by ImmuCell Q4 2024 Earnings Call TranscriptProvided by QuartrFebruary 26, 2025 ShareLink copied to clipboard.There are 4 speakers on the call. Operator00:00:00Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended 12/31/2024, Unaudited Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Joe Diaz of Lytham Partners. Operator00:00:33Please go ahead. Speaker 100:00:36Thank you, Debbie. Good morning and welcome to all. As conference call operator indicated, my name is Joe Diaz. I'm with Lytham Partners. We're the investor relations consulting firm for ImmuCell. Speaker 100:00:50I thank all of you for joining us today to discuss the unaudited financial results for the fourth quarter and the year ended 12/31/2024. Listeners are reminded and cautioned that statements made by management during the course of this call include forward looking statements, which include any statement that refers to future events or expected future results or predictions about the steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today. Additional information regarding forward looking statements and the risks and uncertainties that could impact future results, outcomes or events is available under the cautionary note regarding forward looking statements or better known as Safe Harbor statement provided with the press release that the company filed last night along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Wednesday, 02/26/2025. Speaker 100:02:09The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, President and CEO of ImmuCell Corporation, after which we will open the call for your questions. Michael? Speaker 200:02:54Thanks, Joe, and good morning, everyone. The sales growth of 52% during both the fourth quarter of 'twenty four and during the full year of 2024 in comparison to the same periods of the prior year is huge for us. It should be noted that our performance during 2023 and the first nine months of 2024 was limited by production contamination events that led to a reduction in manufacturing output and delayed effective implementation of our investment in capital expenditures necessary to double our production capacity. This led to a period of short product supply to market as evidenced by our publicly reported backlog of orders. As a result, the 2024 results are compared to periods in 2023 when our production was limited. Speaker 200:03:42The absolute dollar value of the sales is more important to me than the period to period flux comparisons. To that end, the $7,800,000 in sales recorded during the fourth quarter of twenty twenty four suggests that we have achieved our goal of increasing annual production capacity to $30,000,000 or more per year. The results for the fourth quarter of twenty twenty four put us in a much stronger track as we enter 2025. We have not incurred another contamination event since April of twenty twenty four. This is critical. Speaker 200:04:17It suggests that we have effectively remediated the problem and are keeping the bioburden within specification. When I look back, I see something that is now very understandable. After successfully running the same process for over thirty years, sudden growth is hard. We work with a high bioburden source material that being farm milk, we needed to better control quality at the source of this growth. We are doing that now. Speaker 200:04:44Similar challenges were incurred in our downstream processing as we pushed our well established process and equipment harder. We believe that the operational improvements implemented are allowing us to run more effectively at a higher output level going forward. To be successful, we must avoid future significant contamination events and equipment breakdowns and operate with good production yields. We pay our bills and drive our cash flows with gross margin dollars. To that end, gross margin increased by 125% or $1,600,000 to $2,800,000 during the fourth quarter of 'twenty four in comparison to the fourth quarter of twenty twenty three. Speaker 200:05:24And it increased by 105% or $4,100,000 to $7,900,000 during the year ended 12/31/2024, in comparison to the year ended 12/31/2023. We experienced some low gross margin percentages in prior periods as we dealt with low output and scrap costs related to the contaminations. The 36.5% gross margin as a percentage of sales that we recorded during the fourth quarter of 'twenty four is a step in the right direction, but we still have some work to do to return to our target of over 40%. The increase in sales and the improvement in gross margin are important. I take nothing away from those accomplishments, but I would like to talk for a moment about EBITDA because the impact of non cash depreciation expense on our bottom line is significant. Speaker 200:06:12We created EBITDA of $1,300,000 during the fourth quarter of twenty twenty four, in contrast to negative EBITDA of $311,000 during the fourth quarter of twenty twenty three. The fourth quarter results were strong enough to create EBITDA of $1,100,000 during the year ended 12/31/2024, in contrast to negative EBITDA of $2,600,000 during the year ended 12/31/2023. That is a swing in the right direction of approximately $3,700,000 between the years. In order to improve our cash position, we effectively utilized our at the market offering, raising net proceeds of almost $4,400,000 during 2024. This helped us increase our cash position to approximately $3,800,000 as of 12/31/2024 from just $979,000 as of 12/31/2023. Speaker 200:07:09Switching topics a bit, I'd like to offer some comments about Retaine. We remain poised and excited to revolutionize the way that subclinical mastitis is treated in today's dairy market with a novel alternative to traditional antibiotics without FDA required milk discard or meat withhold label restrictions. We are eager to find out what the market thinks of our new product. We can see the potential of achieving FDA approval of RETAIN after all these years of investment. The initiation of our previously disclosed controlled launch is pending FDA clearance of inspectional observations at the facilities of our contract manufacturer and the FDA's review of our non administrative NADA submission, which we submitted during early January of twenty twenty five. Speaker 200:08:01This submission includes all other information and product labeling, as well as our fourth submission of the CMC technical section responding to the minor non complex issues from the incomplete letter issued by the FDA in May of twenty twenty four. We have been in discussions with the FDA to seek an expedited review. After an investment of about twenty five years and approximately $50,000,000 in the development of this technology, we are committed to seeing RETAIN through regulatory approval and initiation of our limited distribution control launch strategy. But at the same time, we are reducing product development expenses as we await FDA approval of RETAIN. We are also in the very early stages of exploring potential strategic options that could offset some of the product development expenses and enhance a mass market launch of RETAIN. Speaker 200:08:55As we work through what we see as the final stages of the regulatory approval process and our effort to bring RETAIN to market, we will remain focused on the commercial opportunity that we have with First Defense. That is the big picture from my perspective. With regards to the other financial results, the press release provides the unaudited P and L results and some unaudited summary balance sheet data. We plan to file our Form 10 K around the March with all the audited financial details and management's discussion and analysis. Lastly, I encourage you to review our corporate presentation slide deck. Speaker 200:09:33I believe it provides a very good summary of our business strategy and objectives as well as our current financial results. The February update was just posted to our website last night. See the Investors section of our website and click on Corporate Presentation or contact us for a copy. With that said, I'll be happy to take your questions. Let's have the operator open up the lines, please. Operator00:09:58We will now begin the question and answer session. The first question comes from George Melas with MKH Management. Please go ahead. Speaker 300:10:42Great. Thank you. Hi, Michael. Good morning. Speaker 200:10:45Hey, good morning, George. How are you? Speaker 300:10:48Very well. Thanks. So congrats on very good results for the quarter. And I want to ask a couple of questions, one on gross margin and the other one on inventory. So on gross margin, you achieved 36.5%, which is the best results in eight quarters. Speaker 300:11:08But like you said, in previous years, like from 'seventeen to 'twenty two to mid 'twenty two, you were consistently having gross margins in the mid to high 40s. So looking at the changes, there's been a few changes. Of course, product mix is different with a bigger share of Tri Shield. Salary costs, I'm sure have gone up, but so has pricing. So I'm trying to see what else accounts for the difference in the gross margin. Speaker 300:11:40And you're saying that your goal is 40%, sort of 40% plus. And what would it take to get there? Speaker 200:11:50Yes. So certainly a lot of factors, but I think the biggest one is I don't want to rank them. I'll comment on a couple. You mentioned product mix. I totally agree with that. Speaker 200:12:04Simply, Tri Shield is more expensive to produce than the bolus. The bolus is a simple bivalent product, a single production train. The Tri Shield is trivalent and involves two production trains. So, Tri Shield product mix, but that's a negative, but the positive is Tri Shield is creating a heck of a lot of growth. The customers really love that broad spectrum coverage with the addition of rotavirus to our long standing E. Speaker 200:12:36Coli and corona. Then I sort of jump off to the 37% in the fourth quarter and I kind of put that in a condition of work in progress. So like you mentioned, way better than the past and still room to go. So 37% is that 24% pricing. So we've got a 25% price increase to help us and the rest we've got to get from yield and throughput. Speaker 200:13:03And those bad periods that we referred to were burdened by contamination, they were burdened by remediation process that slowed down our production. So lower volume, all the impacts there. And that's what I see as I see that turn 24%, twenty five % that we're coming out of that without contamination, with higher production, with a price increase off a fourth quarter base of 37%. Does that make sense? Speaker 300:13:35Okay. Yes. But can you provide a little bit more color on okay, so you're talking about really three factors, the mix, but that's not changing, the price increase that's impacting the gross margin and throughput. But throughput seems pretty optimal almost at this point. So what can you do from an operational perspective, you think? Speaker 300:14:02Or is there much to do from an operational perspective? Speaker 200:14:05Well, first off, more of the same. I mean, we just have to continue that kind of reduction. It's a six month production cycle. We saw a turn here to the better in the fourth quarter. Now we're not projecting. Speaker 200:14:20Now we're managing a repeat, do more of the same, do it better. And I think the one factor we didn't talk about there, but it was related to contamination is yield. So one of our top priorities around here is the same work for more doses, to simply increase production yield. Biological processing is subject to a huge amount of yield variance. And I think we've made some steps and there's always room for more improvement on yield improvement. Speaker 300:14:54And I always say Speaker 200:14:55yield George, I always say yield resumption. It's not like creating a new level of yield, doses per batch or whatever measure you use. It's getting back to the old yields. So it's really putting all of those factors into play in the second three months of this six month period ended March 31. Speaker 300:15:20Okay. So, let me just ask a question on doses per batch. Is there much variation right now in doses to batch? Or has that sort of improved and is relative that is it within a particular a very small range? Or does it vary a great deal from batch to batch? Speaker 200:15:43Yes. I will go with both. I mean, this is biological. This is cows. There's so many different factors. Speaker 200:15:50There's always going to be variance. But I think we've tried and knock off the bottom and try and get more repetition of the better batches. But we're always going to be dealing with yield I mean, that variance and just continual improvement. And that's what we've been seeing. That's related to the 37%. Speaker 300:16:14Okay, great. Okay. So let me ask you just my second question on inventory. So one of the stories over the last two point five years is the big increase in inventory and almost all of that is WIP. So my understanding and I'll just tell you my story, but you tell me whether it's right or wrong, is that as you guys expected growth, you contracted for a lot of milk deliveries, but then there were these unforeseen events, the syringe shortage in mid 'twenty two, the contamination events, and you could not take that. Speaker 300:16:46You could not use that milk, but you still had to take it, it kept deriving, you froze it and that is basically most of the WIP. Is that kind of a correct story? How can you elaborate on that story? Speaker 200:17:04Yes. I think, George, that's all fair. Certainly, growing your real estate or facilities and equipment, people, growing the schedule doesn't do you any good if you don't have more raw material coming in to feed the process. So, yes, we expanded farms, we expanded cows, we expanded colostrum collection. And then the slowdown meant that we didn't need it all at that time, but I wouldn't do it different. Speaker 200:17:32I wouldn't want to be short on Clostrum. And what I think one of the best so if that's a negative, which I see your point, a little negative on the cash flow or where we invest the cash, I think the offsetting and more than offsetting positive is what our really creative sales team is doing with that inventory. And we've talked about this a little, but it's in the development stage of basically a new format. So everything we've been selling, everything we've been making has been freeze dried and a very, very our intellectual property around our manufacturing process is to get a very purified, concentrated and specific antibody. Spray drying is going to be more of a bulk product. Speaker 200:18:15And this excess I hesitate to call it excess, but this level of colostrum enables us to explore that path. A new product format, same concept antibodies, same antibodies, same disease, but just a different market segment being bulk feed rather than a four gram to six gram dose. So I hear your point on cash is king and we watch it super tight. But in this case, I think you can't grow without more incoming. And again, I just credit the sales team for initiating this new format. Speaker 200:19:00And over the coming quarters, we'll be able to report on the success or failure of that initiative. Speaker 300:19:07Okay, great. And timeline, you think whether there might be some the new format might be in beta with some customers or you can give Speaker 200:19:20us Yes. It's a 25 thing that will inform our decisions for '26 and after. So, I think it's the nice thing here is we're not subject to a regulatory hurdle. So, this is going to be a no claim product. It's not a USDA claim product. Speaker 200:19:45So, that allows us to get to market faster, and that's what we're working on. Speaker 300:19:49Okay, great. Okay, thanks a lot. Congratulations again. Speaker 200:19:54Thanks, George. Appreciate Operator00:19:58it. At this time, there are no further questions. So this concludes the question and answer session. I would like to turn the conference back over to Joe Diaz for any closing remarks. Speaker 100:20:20Thanks to all of you for participating on today's call. We look forward to talking with you again to review the results of the first quarter ending 03/31/2025, during the week of 05/12/2025. Have a great day. Again, thanks for participating. Operator00:20:41The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallImmuCell Q4 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsSlide DeckPress Release(8-K)Annual report(10-K) ImmuCell Earnings HeadlinesTop Stock Reports for Netflix, SAP & ShellApril 17 at 11:50 AM | uk.finance.yahoo.comImmuCell appoints new CFO to bolster growth strategyApril 9, 2025 | uk.investing.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. April 19, 2025 | Paradigm Press (Ad)ImmuCell Corporation: ImmuCell Hires Chief Financial OfficerApril 9, 2025 | finanznachrichten.deImmucell reports preliminary Q1 revenue $8.1M vs. $7.3M last yearApril 9, 2025 | markets.businessinsider.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025April 8, 2025 | markets.businessinsider.comSee More ImmuCell Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email. Email Address About ImmuCellImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.View ImmuCell ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 4 speakers on the call. Operator00:00:00Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended 12/31/2024, Unaudited Financial Results Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Joe Diaz of Lytham Partners. Operator00:00:33Please go ahead. Speaker 100:00:36Thank you, Debbie. Good morning and welcome to all. As conference call operator indicated, my name is Joe Diaz. I'm with Lytham Partners. We're the investor relations consulting firm for ImmuCell. Speaker 100:00:50I thank all of you for joining us today to discuss the unaudited financial results for the fourth quarter and the year ended 12/31/2024. Listeners are reminded and cautioned that statements made by management during the course of this call include forward looking statements, which include any statement that refers to future events or expected future results or predictions about the steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes or events to differ materially from those discussed today. Additional information regarding forward looking statements and the risks and uncertainties that could impact future results, outcomes or events is available under the cautionary note regarding forward looking statements or better known as Safe Harbor statement provided with the press release that the company filed last night along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Wednesday, 02/26/2025. Speaker 100:02:09The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non GAAP financial measures may be made during today's call. The company included definitions of these terms as well as reconciliations of these figures to the most comparable GAAP financial measures in last night's press release in order to better assist you in understanding its financial performance. With that said, let me turn the call over to Michael Brigham, President and CEO of ImmuCell Corporation, after which we will open the call for your questions. Michael? Speaker 200:02:54Thanks, Joe, and good morning, everyone. The sales growth of 52% during both the fourth quarter of 'twenty four and during the full year of 2024 in comparison to the same periods of the prior year is huge for us. It should be noted that our performance during 2023 and the first nine months of 2024 was limited by production contamination events that led to a reduction in manufacturing output and delayed effective implementation of our investment in capital expenditures necessary to double our production capacity. This led to a period of short product supply to market as evidenced by our publicly reported backlog of orders. As a result, the 2024 results are compared to periods in 2023 when our production was limited. Speaker 200:03:42The absolute dollar value of the sales is more important to me than the period to period flux comparisons. To that end, the $7,800,000 in sales recorded during the fourth quarter of twenty twenty four suggests that we have achieved our goal of increasing annual production capacity to $30,000,000 or more per year. The results for the fourth quarter of twenty twenty four put us in a much stronger track as we enter 2025. We have not incurred another contamination event since April of twenty twenty four. This is critical. Speaker 200:04:17It suggests that we have effectively remediated the problem and are keeping the bioburden within specification. When I look back, I see something that is now very understandable. After successfully running the same process for over thirty years, sudden growth is hard. We work with a high bioburden source material that being farm milk, we needed to better control quality at the source of this growth. We are doing that now. Speaker 200:04:44Similar challenges were incurred in our downstream processing as we pushed our well established process and equipment harder. We believe that the operational improvements implemented are allowing us to run more effectively at a higher output level going forward. To be successful, we must avoid future significant contamination events and equipment breakdowns and operate with good production yields. We pay our bills and drive our cash flows with gross margin dollars. To that end, gross margin increased by 125% or $1,600,000 to $2,800,000 during the fourth quarter of 'twenty four in comparison to the fourth quarter of twenty twenty three. Speaker 200:05:24And it increased by 105% or $4,100,000 to $7,900,000 during the year ended 12/31/2024, in comparison to the year ended 12/31/2023. We experienced some low gross margin percentages in prior periods as we dealt with low output and scrap costs related to the contaminations. The 36.5% gross margin as a percentage of sales that we recorded during the fourth quarter of 'twenty four is a step in the right direction, but we still have some work to do to return to our target of over 40%. The increase in sales and the improvement in gross margin are important. I take nothing away from those accomplishments, but I would like to talk for a moment about EBITDA because the impact of non cash depreciation expense on our bottom line is significant. Speaker 200:06:12We created EBITDA of $1,300,000 during the fourth quarter of twenty twenty four, in contrast to negative EBITDA of $311,000 during the fourth quarter of twenty twenty three. The fourth quarter results were strong enough to create EBITDA of $1,100,000 during the year ended 12/31/2024, in contrast to negative EBITDA of $2,600,000 during the year ended 12/31/2023. That is a swing in the right direction of approximately $3,700,000 between the years. In order to improve our cash position, we effectively utilized our at the market offering, raising net proceeds of almost $4,400,000 during 2024. This helped us increase our cash position to approximately $3,800,000 as of 12/31/2024 from just $979,000 as of 12/31/2023. Speaker 200:07:09Switching topics a bit, I'd like to offer some comments about Retaine. We remain poised and excited to revolutionize the way that subclinical mastitis is treated in today's dairy market with a novel alternative to traditional antibiotics without FDA required milk discard or meat withhold label restrictions. We are eager to find out what the market thinks of our new product. We can see the potential of achieving FDA approval of RETAIN after all these years of investment. The initiation of our previously disclosed controlled launch is pending FDA clearance of inspectional observations at the facilities of our contract manufacturer and the FDA's review of our non administrative NADA submission, which we submitted during early January of twenty twenty five. Speaker 200:08:01This submission includes all other information and product labeling, as well as our fourth submission of the CMC technical section responding to the minor non complex issues from the incomplete letter issued by the FDA in May of twenty twenty four. We have been in discussions with the FDA to seek an expedited review. After an investment of about twenty five years and approximately $50,000,000 in the development of this technology, we are committed to seeing RETAIN through regulatory approval and initiation of our limited distribution control launch strategy. But at the same time, we are reducing product development expenses as we await FDA approval of RETAIN. We are also in the very early stages of exploring potential strategic options that could offset some of the product development expenses and enhance a mass market launch of RETAIN. Speaker 200:08:55As we work through what we see as the final stages of the regulatory approval process and our effort to bring RETAIN to market, we will remain focused on the commercial opportunity that we have with First Defense. That is the big picture from my perspective. With regards to the other financial results, the press release provides the unaudited P and L results and some unaudited summary balance sheet data. We plan to file our Form 10 K around the March with all the audited financial details and management's discussion and analysis. Lastly, I encourage you to review our corporate presentation slide deck. Speaker 200:09:33I believe it provides a very good summary of our business strategy and objectives as well as our current financial results. The February update was just posted to our website last night. See the Investors section of our website and click on Corporate Presentation or contact us for a copy. With that said, I'll be happy to take your questions. Let's have the operator open up the lines, please. Operator00:09:58We will now begin the question and answer session. The first question comes from George Melas with MKH Management. Please go ahead. Speaker 300:10:42Great. Thank you. Hi, Michael. Good morning. Speaker 200:10:45Hey, good morning, George. How are you? Speaker 300:10:48Very well. Thanks. So congrats on very good results for the quarter. And I want to ask a couple of questions, one on gross margin and the other one on inventory. So on gross margin, you achieved 36.5%, which is the best results in eight quarters. Speaker 300:11:08But like you said, in previous years, like from 'seventeen to 'twenty two to mid 'twenty two, you were consistently having gross margins in the mid to high 40s. So looking at the changes, there's been a few changes. Of course, product mix is different with a bigger share of Tri Shield. Salary costs, I'm sure have gone up, but so has pricing. So I'm trying to see what else accounts for the difference in the gross margin. Speaker 300:11:40And you're saying that your goal is 40%, sort of 40% plus. And what would it take to get there? Speaker 200:11:50Yes. So certainly a lot of factors, but I think the biggest one is I don't want to rank them. I'll comment on a couple. You mentioned product mix. I totally agree with that. Speaker 200:12:04Simply, Tri Shield is more expensive to produce than the bolus. The bolus is a simple bivalent product, a single production train. The Tri Shield is trivalent and involves two production trains. So, Tri Shield product mix, but that's a negative, but the positive is Tri Shield is creating a heck of a lot of growth. The customers really love that broad spectrum coverage with the addition of rotavirus to our long standing E. Speaker 200:12:36Coli and corona. Then I sort of jump off to the 37% in the fourth quarter and I kind of put that in a condition of work in progress. So like you mentioned, way better than the past and still room to go. So 37% is that 24% pricing. So we've got a 25% price increase to help us and the rest we've got to get from yield and throughput. Speaker 200:13:03And those bad periods that we referred to were burdened by contamination, they were burdened by remediation process that slowed down our production. So lower volume, all the impacts there. And that's what I see as I see that turn 24%, twenty five % that we're coming out of that without contamination, with higher production, with a price increase off a fourth quarter base of 37%. Does that make sense? Speaker 300:13:35Okay. Yes. But can you provide a little bit more color on okay, so you're talking about really three factors, the mix, but that's not changing, the price increase that's impacting the gross margin and throughput. But throughput seems pretty optimal almost at this point. So what can you do from an operational perspective, you think? Speaker 300:14:02Or is there much to do from an operational perspective? Speaker 200:14:05Well, first off, more of the same. I mean, we just have to continue that kind of reduction. It's a six month production cycle. We saw a turn here to the better in the fourth quarter. Now we're not projecting. Speaker 200:14:20Now we're managing a repeat, do more of the same, do it better. And I think the one factor we didn't talk about there, but it was related to contamination is yield. So one of our top priorities around here is the same work for more doses, to simply increase production yield. Biological processing is subject to a huge amount of yield variance. And I think we've made some steps and there's always room for more improvement on yield improvement. Speaker 300:14:54And I always say Speaker 200:14:55yield George, I always say yield resumption. It's not like creating a new level of yield, doses per batch or whatever measure you use. It's getting back to the old yields. So it's really putting all of those factors into play in the second three months of this six month period ended March 31. Speaker 300:15:20Okay. So, let me just ask a question on doses per batch. Is there much variation right now in doses to batch? Or has that sort of improved and is relative that is it within a particular a very small range? Or does it vary a great deal from batch to batch? Speaker 200:15:43Yes. I will go with both. I mean, this is biological. This is cows. There's so many different factors. Speaker 200:15:50There's always going to be variance. But I think we've tried and knock off the bottom and try and get more repetition of the better batches. But we're always going to be dealing with yield I mean, that variance and just continual improvement. And that's what we've been seeing. That's related to the 37%. Speaker 300:16:14Okay, great. Okay. So let me ask you just my second question on inventory. So one of the stories over the last two point five years is the big increase in inventory and almost all of that is WIP. So my understanding and I'll just tell you my story, but you tell me whether it's right or wrong, is that as you guys expected growth, you contracted for a lot of milk deliveries, but then there were these unforeseen events, the syringe shortage in mid 'twenty two, the contamination events, and you could not take that. Speaker 300:16:46You could not use that milk, but you still had to take it, it kept deriving, you froze it and that is basically most of the WIP. Is that kind of a correct story? How can you elaborate on that story? Speaker 200:17:04Yes. I think, George, that's all fair. Certainly, growing your real estate or facilities and equipment, people, growing the schedule doesn't do you any good if you don't have more raw material coming in to feed the process. So, yes, we expanded farms, we expanded cows, we expanded colostrum collection. And then the slowdown meant that we didn't need it all at that time, but I wouldn't do it different. Speaker 200:17:32I wouldn't want to be short on Clostrum. And what I think one of the best so if that's a negative, which I see your point, a little negative on the cash flow or where we invest the cash, I think the offsetting and more than offsetting positive is what our really creative sales team is doing with that inventory. And we've talked about this a little, but it's in the development stage of basically a new format. So everything we've been selling, everything we've been making has been freeze dried and a very, very our intellectual property around our manufacturing process is to get a very purified, concentrated and specific antibody. Spray drying is going to be more of a bulk product. Speaker 200:18:15And this excess I hesitate to call it excess, but this level of colostrum enables us to explore that path. A new product format, same concept antibodies, same antibodies, same disease, but just a different market segment being bulk feed rather than a four gram to six gram dose. So I hear your point on cash is king and we watch it super tight. But in this case, I think you can't grow without more incoming. And again, I just credit the sales team for initiating this new format. Speaker 200:19:00And over the coming quarters, we'll be able to report on the success or failure of that initiative. Speaker 300:19:07Okay, great. And timeline, you think whether there might be some the new format might be in beta with some customers or you can give Speaker 200:19:20us Yes. It's a 25 thing that will inform our decisions for '26 and after. So, I think it's the nice thing here is we're not subject to a regulatory hurdle. So, this is going to be a no claim product. It's not a USDA claim product. Speaker 200:19:45So, that allows us to get to market faster, and that's what we're working on. Speaker 300:19:49Okay, great. Okay, thanks a lot. Congratulations again. Speaker 200:19:54Thanks, George. Appreciate Operator00:19:58it. At this time, there are no further questions. So this concludes the question and answer session. I would like to turn the conference back over to Joe Diaz for any closing remarks. Speaker 100:20:20Thanks to all of you for participating on today's call. We look forward to talking with you again to review the results of the first quarter ending 03/31/2025, during the week of 05/12/2025. Have a great day. Again, thanks for participating. Operator00:20:41The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by